# Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Source: https://onco.cc/trials/nct05316701/  
OnCo record `nct05316701` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Orca-T in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by Orca Biosystems, Inc., active and no longer recruiting.

## Summary

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies is a phase 3 interventional study registered as NCT05316701 by Orca Biosystems, Inc., with 187 participants enrolled, started 2022-06-21 and due to reach its primary completion in 2024-07-15. Interventions recorded: Orca-T and Standard-of-Care. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05316701
- Phase: 3
- Setting: A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
- Sponsor: Orca Biosystems, Inc.
- Enrolled: 187

## Sources

- ClinicalTrials.gov NCT05316701: https://clinicaltrials.gov/study/NCT05316701

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- companies: [Orca Biosystems](https://onco.cc/companies/orca-biosystems/)

---
JSON: https://onco.cc/api/v1/entities/nct05316701.json